{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444132346
| IUPAC_name = 2,4-dimethyl-8-{[2'-(1''H''-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-''d'']pyrimidin-7(6''H'')-one
| image = tasosartan.png

<!--Clinical data-->
| tradename =  
| pregnancy_category = N/A
| legal_status = Withdrawn
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 6898
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 145733-36-4
| ATC_prefix = C09
| ATC_suffix = CA05
| PubChem = 60919
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01349
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 54890
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 48G92V856H

<!--Chemical data-->
| C=23 | H=21 | N=7 | O=1 
| molecular_weight = 411.459 g/mol
}}

'''Tasosartan''' is an [[angiotensin II receptor antagonist]].

It was withdrawn from FDA review by the manufacturer after [[clinical trials#Phase III|phase III clinical trials]] showed [[elevated transaminases]] (a sign of possible [[hepatotoxicity|liver toxicity]]) in a significant number of participants given the drug.<ref>{{cite book  |vauthors=Atkinson AJ, etal |title=Principles of clinical pharmacology |publisher=Elsevier |location=Amsterdam |year=2007 |page=515 |isbn=0-12-369417-5}}</ref><ref>{{cite journal |vauthors=Dina R, Jafari M |title=Angiotensin II-receptor antagonists: an overview |journal=Am J Health Syst Pharm |volume=57 |issue=13 |pages=1231â€“41 |date=July 2000 |pmid=10902066 |url=http://www.medscape.com/viewarticle/406895}}</ref>

==References==
{{Reflist|2}}

{{Agents acting on the renin-angiotensin system}}
{{Angiotensin receptor modulators}}

[[Category:Tetrazoles]]
[[Category:Pyridopyrimidines]]
[[Category:Lactams]]
[[Category:Angiotensin II receptor antagonists]]
[[Category:Biphenyls]]


{{cardiovascular-drug-stub}}